Apriso Uses

Apriso is a medication that is used for treating ulcerative colitis in adults. Specifically, it is approved to help keep ulcerative colitis symptoms away in people who are currently in remission (who are experiencing no symptoms or only very mild symptoms). Healthcare providers may also occasionally recommend off-label uses of Apriso, such as for treating Crohn's disease.

What Is Apriso Used For?

Apriso™ (mesalamine) is a prescription medicine approved to treat ulcerative colitis. It is part of a group of medications known as aminosalicylates. It is a long-acting form of mesalamine that is taken just once a day in the morning.
Ulcerative colitis is a type of inflammatory bowel disease (IBD) that leads to inflammation and sores in the lining of the large intestine and rectum. Symptoms of ulcerative colitis often include abdominal pain, diarrhea, and other symptoms like rectal bleeding or extreme urgency to have a bowel movement. At this time, the causes of ulcerative colitis are not fully understood.
Although ulcerative colitis complications can be quite severe, there is one ulcerative colitis cure -- surgery. Other than surgery (see Ulcerative Colitis Surgery), other treatment options include the following:
Many people seem to get better on their own (or with medications, dietary changes, or lifestyle changes). This is known as remission, but it is not usually permanent. Most people cycle between remissions and relapses. Apriso is approved for "maintenance remission" of ulcerative colitis in adults. This means that it is approved to help keep symptoms away in people who are currently experiencing no symptoms (or only very mild symptoms).

Apriso Drug Information

Referring Pages:
Terms of Use
Advertise with Us
Contact Us
About eMedTV
Privacy Policy
Copyright © 2006-2019 Clinaero, Inc.
eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind. Site users seeking medical advice about their specific situation should consult with their own physician. Click Terms of Use for more information.